Lonza, the world's leading contract development and manufacturing organization (CDMO), has announced its participation in the Jefferies Global Healthcare Conference in London on 17 and 18 November 2026. CEO Wolfgang Wienand will host a presentation and subsequent Q&A session on 18 November from 15:30 to 15:55 GMT (16:30 to 16:55 CET). The session will be webcast live, and a replay will be available on the Lonza Investor Relations website for 90 days. The live audio webcast can be accessed via this link.
The announcement, issued via NEWMEDIAWIRE, positions Lonza to engage directly with the investment community at a prominent healthcare conference. As a CDMO serving the healthcare industry across three continents, Lonza works alongside pharma and biotech companies to turn breakthrough innovations into viable therapies. With approximately 17,000 colleagues, the company enables customers to bring life-saving and life-enhancing treatments to patients worldwide through a combination of cutting-edge science, smart technology, and lean manufacturing.
For investors and industry observers, Wienand's presentation and Q&A represent a key opportunity to gain insights into Lonza's strategy and performance. The company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026, underscoring its significant scale and financial strength. Participation in the Jefferies conference signals Lonza's ongoing commitment to transparency and engagement with the global healthcare investment community. More information about Lonza can be found at www.lonza.com.
The webcast and replay accessibility extends the reach of the presentation beyond conference attendees, allowing a broader audience of investors, analysts, and stakeholders to hear directly from Lonza's leadership. This is particularly important given the CDMO sector's critical role in the healthcare ecosystem, where manufacturing and development partnerships are essential for bringing new therapies to market. Lonza's presence at the Jefferies conference highlights its position as a key player in the industry and provides a platform to discuss trends, challenges, and opportunities shaping the future of healthcare manufacturing.
Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange with a secondary listing on the Singapore Exchange Securities Trading Limited. The company's participation in the Jefferies Global Healthcare Conference aligns with its dedication to serving the healthcare industry and driving innovation. As the conference date approaches, stakeholders can look forward to Wienand's insights on Lonza's performance and strategic direction, which may have implications for the broader CDMO market and the patients who ultimately benefit from the therapies developed and manufactured by Lonza and its partners.
